About Us

History

Bio-Technology General (Israel) Ltd. (BTG) was founded in October 1980 by Professor Haim Aviv and colleagues from the Weizmann Institute of Science in order to take advantage of what was then the new science of genetic engineering. The company was established as a wholly-owned subsidiary of Bio-Technology General Corp. in New York, with a primary mission of developing and manufacturing human health care products, primarily those derived from genetic engineering and biotechnology processes. BTG, one of the first such companies in Israel as well as in the world, was initially located in the Kiryat Weizmann Science Park adjacent to the Weizmann Institute.

In addition to its pharmaceutical pursuits, BTG was also involved at the outset in agricultural projects such as animal growth hormones, foot and mouth disease vaccine, Azopirillum, etc., but by the mid 1980’s terminated its agricultural pursuits to focus entirely on human health care products. During this period, BTG Corp. went public on the NASDAQ; BTG Corp. later changed its name to Savient Pharmaceuticals Inc.

BTG obtained initial product regulatory approvals in the late 1980’s and throughout the 1990’s. In 1999, the company acquired a site in Beer Tuvia, built a new facility on the site and during the period 2003-2007 moved to the Beer Tuvia facility and closed the Kiryat Weizmann plant. In 2005, BTG was sold by Savient to Ferring Pharmaceuticals, a privately-held, multinational company headquartered in Switzerland.

Today, more than 300 BTG employees at the Beer Tuvia site are still engaged in the development, manufacture and marketing of health care products derived from genetic engineering and biotechnology processes, and the company is a Center for Excellence in Biotechnology for Ferring’s Development and Manufacturing networks.

BTG in Kiryat Weizmann
Shift to Pharmaceutical Culture, 1990-1997

HISTORIC TIMELINE

1980

BTG founded, begins work on Azospirillum, Trichoderma, Foot & Mouth Disease, Bovine Growth Hormone

1982

Work begins on NaHA, Human  Growth Hormone

1983

Agreement with American Cyanamid on bGH development

 

1985

Agreement with Pharmacia on NaHA development

1987

Move to building 17, Kiryat Weizmann

1988

Human Growth hormone approved by Israel Ministry of Health

1992

Human Growth hormone  approved by EMEA in first approval by new centralized procedure

1992

Agreement with Ferring on hGH November 9, 1992

1993

Human Growth hormone  approval in Japan for short stature

1995

Biolon approved in Europe (CE mark)

1995

Human Growth hormone  approved by US FDA

1997

Recombinant insulin licensed to Bioton and to Diosynth

1998

Agreement with JCR on hGH October 10, 1988

1999

Beer Tuvia site acquired

2000

Bio-Hep-B (company’s Hepatitis B vaccine) approval in Israel

2001

Arthrease (EUFLEXXA) approved in Europe (CE mark) and Israel

2004

Move to Beer Tuvia

 

2004

EUFLEXXA approved by US FDA

2005

BTG acquired by Ferring

2010

Pegloticase approved by US FDA

2016

REKOVELLE was first approved in EU

2017

REKOVELLE was approved in Australia, Brazil, Israel, Switzerland, Canada and Mexico.

2018

Agreement with Altacor/Amring